| |
| |
|
| Insider
Information: |
Nashat Amir |
| Relationship: |
Director, 10% Owner |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
38,223 |
|
|
Indirect Shares
|
5,311,169 |
|
|
| Direct
Value |
$379,279 |
|
|
|
Indirect Value
|
$37,966,189 |
|
|
| Total
Shares |
5,349,392 |
|
|
| Total
Value |
$38,345,468 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
1
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 89.2%
|
 -3.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Receptos, Inc. |
RCPT |
Director |
2013-05-14 |
0 |
2014-05-27 |
274 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2013-10-04 |
0 |
2019-08-01 |
11,034 |
Premium* |
|
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
12,572 |
2015-05-12 |
17,638 |
Premium* |
|
|
Selecta Biosciences Inc |
SELB |
Director |
|
0 |
2019-01-25 |
2,676,234 |
Premium* |
|
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director, 10% Owner |
2016-07-06 |
0 |
2016-07-06 |
48,320 |
Premium* |
|
|
Scholar Rock Holding Corp |
SRRK |
|
2023-12-27 |
25,506 |
2023-12-27 |
2,248,574 |
Premium* |
|
|
Morphic Holding, Inc. |
MORF |
Director |
2023-06-28 |
145 |
2023-06-28 |
130,153 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
Director, 10% Owner |
2020-09-18 |
0 |
2020-09-18 |
178,942 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
21,333 |
25,506 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
26,265 |
46,839 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-12-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,197,068) |
0 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-12-13 |
4 |
A |
$0.00 |
$0 |
I/I |
197,711 |
548 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
13,133 |
20,574 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(598,537) |
0 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
|
– • – |
2023-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
98,859 |
276 |
0 |
- |
|
| MORF |
Morphic Holding, Inc. |
Director |
– • – |
2023-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
935 |
935 |
0 |
- |
|
| MORF |
Morphic Holding, Inc. |
Director |
– • – |
2023-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
145 |
145 |
0 |
- |
|
| MORF |
Morphic Holding, Inc. |
Director |
– • – |
2023-06-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(100,935) |
130,153 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
Director |
– • – |
2022-06-22 |
4 |
B |
$4.90 |
$5,870,161 |
I/I |
1,197,992 |
206,897 |
2.1 |
% |
|
| SRRK |
Scholar Rock Holding Corp |
Director |
– • – |
2021-11-17 |
4 |
A |
$0.00 |
$0 |
D/D |
7,441 |
7,441 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
Director |
– • – |
2021-11-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(339,098) |
0 |
0 |
- |
|
| SRRK |
Scholar Rock Holding Corp |
Director |
– • – |
2021-11-17 |
4 |
A |
$0.00 |
$0 |
I/I |
56,009 |
160 |
0 |
- |
|
| MORF |
Morphic Holding, Inc. |
Director |
– • – |
2021-05-21 |
4 |
S |
$45.50 |
$10,569,423 |
I/I |
(232,295) |
136,691 |
0 |
% |
|
| MTCR |
Metacrine, Inc. |
Director |
– • • |
2020-09-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,664,258 |
178,942 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
Director |
– • • |
2020-09-18 |
4 |
B |
$13.00 |
$2,990,000 |
I/I |
230,000 |
15,038 |
2.25 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-08-01 |
4 |
AS |
$22.53 |
$695,392 |
I/I |
(30,866) |
11,034 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-31 |
4 |
AS |
$22.53 |
$701,674 |
I/I |
(31,139) |
11,333 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-30 |
4 |
AS |
$22.51 |
$2,029,560 |
I/I |
(90,175) |
11,635 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-29 |
4 |
AS |
$22.50 |
$7,403 |
I/I |
(329) |
12,508 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-26 |
4 |
AS |
$22.50 |
$626,153 |
I/I |
(27,829) |
12,511 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-24 |
4 |
AS |
$22.51 |
$447,098 |
I/I |
(19,866) |
12,781 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-23 |
4 |
AS |
$22.51 |
$1,396,053 |
I/I |
(62,033) |
12,973 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • – |
2019-07-22 |
4 |
AS |
$22.52 |
$1,097,019 |
I/I |
(48,704) |
13,574 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
